Video

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

Author(s):

Benjamin Levy, MD

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Related Videos
Phase 3 AMPLIFY Trial
Hidehito Horinouchi, MD, PhD
RLY-2608
Ewa Kalinka, MD, PhD
BOVen
RMC-6236
Related Content
Alexander Watson, MD, DPhil, FRCPC, of University of Colorado Denver
January 28th 2025

Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

Limertinib for EGFR T790M+ NSCLC | Image Credit: © catalin – stock.adobe.com
January 17th 2025

Limertinib Wins Approval in China for EGFR T790M+ NSCLC